After hours: September 20 at 4:05 PM EDT ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

LONDON, England—Use of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone cuts the risk of worsening HF events and cardiovascular mortality in patients who have heart failure with ...

Circulation 2024;Sep 10:[Epub ahead of print]. The following are key points to remember from a scientific statement on the evaluation and management of kidney dysfunction in advanced heart failure (HF ...

This repository accompanies our CVPR 2019 paper From Coarse to Fine: Robust Hierarchical Localization at Large Scale. We introduce a 6-DoF visual localization method that is accurate, scalable, and ...

Finerenone reduced the risk of cardiovascular (CV) death and total heart failure (HF) events in patients with HF with mildly reduced or preserved ejection fraction, according to results from a phase 3 ...

Highlighted text has been updated as of August 30, 2024. The PARAGON-HF trial failed to show that sacubitril/valsartan reduced adverse events among patients with HFpEF. Patients with HFpEF were ...

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

Marine forecasts and warnings are broadcast to mariners over High Frequency (HF) radio from Charleville (VMC) for eastern waters and Wiluna (VMW) for western waters. The service comprises: Marine ...

Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...

According to Stefan Anker, MD, PhD (Charité Universitätsmedizin Berlin, Germany), who presented RESHAPE-HF2 at ESC, the results are a clear win for the MitraClip (Abbott), which was superior to OMT ...